Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 4
2016 2
2017 8
2018 7
2019 11
2020 10
2021 9
2022 5
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean solen brosseau (1 results)?
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Routy B, et al. Among authors: brosseau s. Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2. Science. 2018. PMID: 29097494
Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer.
Chour A, Denis J, Mascaux C, Zysman M, Bigay-Game L, Swalduz A, Gounant V, Cortot A, Darrason M, Fallet V, Auclin E, Basse C, Tissot C, Decroisette C, Bombaron P, Giroux-Leprieur E, Odier L, Brosseau S, Creusot Q, Gueçamburu M, Meersseman C, Rochand A, Costantini A, Gaillard CM, Wasielewski E, Girard N, Cadranel J, Lafitte C, Lebossé F, Duruisseaux M. Chour A, et al. Among authors: brosseau s. J Thorac Oncol. 2023 Oct;18(10):1408-1415. doi: 10.1016/j.jtho.2023.05.013. Epub 2023 May 20. J Thorac Oncol. 2023. PMID: 37217096
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C. Ferrara R, et al. Among authors: brosseau s. JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676. JAMA Oncol. 2018. PMID: 30193240 Free PMC article.
Immunotherapy in relapsed mesothelioma.
Brosseau S, Dhalluin X, Zalcman G, Scherpereel A. Brosseau S, et al. Immunotherapy. 2018 Feb;10(2):77-80. doi: 10.2217/imt-2017-0144. Immunotherapy. 2018. PMID: 29260624 Free article. No abstract available.
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B. Mezquita L, et al. Among authors: brosseau s. JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771. JAMA Oncol. 2018. PMID: 29327044 Free PMC article.
Antiangiogeneic Strategies in Mesothelioma.
Nowak AK, Brosseau S, Cook A, Zalcman G. Nowak AK, et al. Among authors: brosseau s. Front Oncol. 2020 Feb 18;10:126. doi: 10.3389/fonc.2020.00126. eCollection 2020. Front Oncol. 2020. PMID: 32133285 Free PMC article. Review.
[Initial assessment of lung cancer].
Pluvy J, Brosseau S, Soussi G, Zalcman G, Gounant V. Pluvy J, et al. Among authors: brosseau s. Rev Prat. 2020 Dec;70(10):1111-1120. Rev Prat. 2020. PMID: 33739658 Review. French.
Bevacizumab in advanced lung cancer: state of the art.
Assoun S, Brosseau S, Steinmetz C, Gounant V, Zalcman G. Assoun S, et al. Among authors: brosseau s. Future Oncol. 2017 Dec;13(28):2515-2535. doi: 10.2217/fon-2017-0302. Epub 2017 Aug 16. Future Oncol. 2017. PMID: 28812378 Review.
Management of immune-related adverse events resulting from immune checkpoint blockade.
Baroudjian B, Arangalage D, Cuzzubbo S, Hervier B, Lebbé C, Lorillon G, Tazi A, Zalcman G, Bouattour M, Lioté F, Gautier JF, Brosseau S, Lourenco N, Delyon J; PATIO group. Baroudjian B, et al. Among authors: brosseau s. Expert Rev Anticancer Ther. 2019 Mar;19(3):209-222. doi: 10.1080/14737140.2019.1562342. Epub 2019 Jan 9. Expert Rev Anticancer Ther. 2019. PMID: 30572735 Review.
53 results